natgillin/translations-raw huggingface dataset:
Kontakt straks en læge, hvis du får nogen af disse symptomer.
Contact a doctor immediately if you get any of these symptoms.
Væskeophobning og hjertesvigt:
Fluid retention and heart failure:
Avaglim kan være årsag til, at der ophobes væske i din krop, hvilket medfører hævelse og vægtøgning.
Avaglim can cause you to retain water (fluid retention) which leads to swelling and weight gain.
Ekstra kropsvæske kan forværre eksisterende hjertelidelser eller medføre hjertesvigt.
Extra body fluid can make some existing heart problems worse or lead to heart failure.
Tjek din vægt jævnligt.
This is more likely if you are also taking other medicines for your diabetes like insulin, if you have kidney problems, or if you are over 65.
Symptomerne på hjertesvigt omfatter: • åndenød og opvågnen i løbet af natten pga. åndenød • hurtig træthed efter let fysisk aktivitet såsom gang • hurtig vægtøgning • hævede ankler eller fødder.
Symptoms of heart failure include: • shortness of breath, waking up short of breath at night • getting tired easily after light physical activity such as walking • rapid increase in your weight • swollen ankles or feet.
Fortæl det til lægen så hurtigt så muligt, hvis du får nogen af disse symptomer – både hvis symptomerne forekommer for første gang eller hvis de bliver værre.
Tell your doctor as soon as possible if you get any of these symptoms - either for the first time or if they get worse.
Lavt blodsukker (hypoglykæmi):
Low blood sugar (hypoglycaemia):
Særlige forhold gør dig mere udsat for at få for lavt blodsukker, mens du er i behandling med Avaglim.
Certain conditions can make you more likely to suffer from low blood sugar while you are taking Avaglim.
Disse er følgende: • samtidig brug af andre lægemidler til behandling af diabetes • nyresygdom • lav kropsvægt eller fejlernæring • stressede situationer (såsom traume, operation eller infektioner) De første symptomer på lavt blodsukker er: • rysten, sved, besvimelse • nervøsitet, hjertebanken • sult.
These include: taking other medicines to treat diabetes kidney disease low body weight or poor diet stress situations (such as trauma, surgery or infections) Early symptoms of low blood sugar are: shaking, sweating, faintness nervousness, palpitations hunger.
Fortæl det til lægen så hurtigt så muligt, hvis du får nogen af disse symptomer.
Tell your doctor as soon as possible if you get any of these symptoms.
Inden og i løbet af behandlingen med Avaglim, vil din læge tage blodprøver for at tjekke din leverfunktion.
This check may be repeated at intervals.
Følgende symptomer kan være tegn på leverproblemer: • kvalme og opkastning • mavesmerter • appetitløshed • mørk urin.
These may be signs of liver problems: • nausea and vomiting • stomach (abdominal) pain • loss of appetite • dark-coloured urine.
Fortæl det til lægen så hurtigt så muligt, hvis du får disse symptomer.
Tell your doctor as soon as possible if you get these symptoms.
Øjenlidelser:
Eye problems:
Diabetespatienter kan opleve problemer i form af hævelse af retina i det bagerste af øjet, hvilket kan medføre synsforstyrrelser (maculaødem).
Swelling of the retina at the back of the eye which can cause blurred vision (macular oedema) can be a problem for people with diabetes.
Tal med lægen, hvis du har bekymringer vedrørende dit syn.
Discuss with your doctor any concerns about your eyesight.
49 Knoglebrud:
Broken bones:
Knoglebrud kan forekomme hos patienter med diabetes.
Bone fractures can occur in people with diabetes.
Risikoen er større hos kvinder, der har taget rosiglitazon i mere end et år.
The chances of this happening may be higher in women taking rosiglitazone for more than one year.
Meget almindelige bivirkninger Disse kan påvirke mere end 1 ud af 10 patienter: • lavere blodsukker end normalt (hypoglykæmi) • hævelse (ødem) på grund af væskeophobning.
48 Very common side effects These may affect more than 1 in 10 people: • lower blood sugar than normal (hypoglycaemia) • swelling (oedema) due to water retention.
Almindelige bivirkninger Disse kan påvirke op til 1 ud af 10 patienter: • brystsmerter (angina) • hjertesvigt • knoglebrud • øget vægt, øget appetit • svimmelhed • forstoppelse • fald i antallet af blodlegemer (anæmi), herunder hvide blodlegemer (leukopeni) og blodlegemer der har en koagulerende virkning (thrombocytopeni) • lille stigning af kolesterol i blodet, øget fedtindhold i blodet.
Common side effects These may affect up to 1 in 10 people: • chest pain (angina) • heart failure • broken bones • increased weight, increased appetite • dizziness • constipation • reduction in blood count (anaemia) low numbers of white blood cells (leucopaenia) and blood cells needed for blood clotting (thrombocytopaenia) • small increases in blood cholesterol, increased amount of fats in the blood
Sjældne bivirkninger Disse kan påvirke op til 1 ud af 1. 000 patienter: • væske i lungerne (lungeødem) som kan forårsage stakåndethed • hævelse af retina i det bagerste af øjet (maculaødem) • fald i antallet af røde blodlegemer eller fald i antallet af en speciel type hvide blodlegemer (granulocytopeni), som kan være alvorlig (agranulocytose), fald i antallet af alle typer blodlegemer (pancytopeni) • nedsat leverfunktion (forhøjede leverenzymer).
Rare side effects These may affect up to 1 in 1,000 people: • fluid in the lungs (pulmonary oedema) causing breathlessness • swelling of the retina at the back of the eye (macular oedema) • reduction in the number of red blood cells, or a type of white blood cell (granulocytopaenia) which can be severe (agranulocytosis), reduction in the number of all types of blood cells (pancytopaenia) • liver doesn’ t function as well as it should (increase in liver enzymes).
Meget sjældne bivirkninger Disse kan påvirke op til 1 ud af 10. 000 patienter: • allergiske reaktioner, betændelse af blodkar (allergisk vaskulit) • øget følsomhed over for sollys med udslæt til følge • leverbetændelse (hepatitis), gulfarvning af huden (gulsot) • hurtig og voldsom vægtøgning på grund af væskeophobning • mavesmerter, oppustethed, kvalme, opkastning og diarré • nedsat mængde af natrium i blodet.
Very rare side effects These may affect up to 1 in 10,000 people: • allergic reactions, inflammation of blood vessels (allergic vasculitis) • increased sensitivity to the sun causing skin rash • inflammation of the liver (hepatitis), yellowing of the skin (jaundice) • rapid and excessive weight gain caused by fluid retention • stomach pain, bloating, feeling sick (nausea), vomiting or diarrhoea • decrease in the amount of sodium in your blood.
Hvis du får bivirkninger Tal med lægen eller apoteket, hvis en bivirkning bliver værre, eller du får bivirkninger, som ikke er nævnt her.
If you get side effects Tell your doctor or pharmacist if any of the side effects listed gets severe or troublesome, or if you notice any side effects not listed in this leaflet.
SÅDAN OPBEVARER DU AVAGLIM
HOW TO STORE AVAGLIM
Spørg på apoteket, hvordan du skal aflevere medicinrester.
If you have any unwanted tablets, don’ t put them in waste water or household rubbish.
50 6.
49 6.
Avaglim indeholder De aktive stoffer er rosiglitazon og glimepirid.
What Avaglim contains The active substances are rosiglitazone and glimepiride.
En tablet indeholder enten:
Each tablet contains either:
4 mg eller 8 mg rosiglitazon og 4 mg glimepirid.
4 mg or 8 mg rosiglitazone and 4 mg glimepiride.
De øvrige indholdsstoffer er natriumstivelsesglycollat (type A), hypromellose (E464), mikrokrystallinsk cellulose (E460), lactosemonohydrat, magnesiumstearat, titandioxid (E171), macrogol 400, sort og/ eller rød jernoxid (E172).
The other ingredients are: sodium starch glycollate (Type A), hypromellose (E464), microcrystalline cellulose (E460), lactose monohydrate, magnesium stearate, titanium dioxide (E171), macrogol 400, iron oxide black and/ or red (E172).
De er præget ” gsk ” på den ene side og ” 4/ 4 ” på den anden.
What Avaglim looks like and contents of the pack Avaglim 4 mg/ 4 mg tablets are pink, rounded triangular-shaped, and marked "gsk" on one side and "4/ 4" on the other.
De er præget ” gsk ” på den ene side og ” 8/ 4 ” på den anden.
Avaglim 8 mg/ 4 mg tablets are red, rounded triangular-shaped, and marked "gsk" on one side and "8/ 4" on the other.
SmithKline Beecham plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK.
SmithKline Beecham plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.
Glaxo Wellcome S. A., Avenida de Extremadura, 3, 09400 Aranda de Duero, Burgos, Spanien.
Glaxo Wellcome S. A., Avenida de Extremadura 3, 09400 Aranda de Duero, Burgos, Spain.
51 Hvis du vil have yderligere oplysninger om Avaglim, skal du henvende dig til den lokale repræsentant:
50 For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
Italia GlaxoSmithKline S. p. A.
51 Italia GlaxoSmithKline S. p. A.
52 Κύπρος GlaxoSmithKline Cyprus Ltd Τηλ: + 357 22 89 95 01
Κύπρος GlaxoSmithKline Cyprus Ltd Τηλ: + 357 22 89 95 01
Du kan finde yderligere information om Avaglim på Det europæiske Lægemiddelagenturs (EMEAs) hjemmeside http: // www. emea. europa. eu
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/
Hvad er AVAMYS?
What is AVAMYS?
AVAMYS er en næsespray, der indeholder det aktive stof fluticasonfuroat.
AVAMYS is a nasal spray that contains the active substance fluticasone furoate.
Hvad anvendes AMASYS til?
What is AVAMYS used for?
AVAMYS anvendes til at behandle symptomerne af allergisk rhinitis.
AVAMYS is used to treat the symptoms of allergic rhinitis.
Dette er ofte ledsaget af symptomer, der påvirker øjnene, som f. eks. irriterede, løbende og røde øjne.
It is often accompanied by symptoms affecting the eyes, such as irritation, watering or redness.
AVAMYS kan anvendes af voksne og børn fra seks år.
AVAMYS is for use in adults and children aged six years and over.
Hvordan anvendes AVAMYS?
How is AVAMYS used?
Den anbefalede dosis AVAMYS for voksne og unge fra 12 år er to pust i hvert næsebor en gang om dagen.
The recommended dose of AVAMYS for adults and adolescents aged 12 years and over is two sprays in each nostril once a day.
Den begynder typisk at virke fra otte timer efter første pust, dog kan det vare adskillige dage, før man oplever det fulde udbytte.
It usually starts to work from eight hours after the first spray, but it may take several days to get the maximum benefit.
AVAMYS må kun bruges så længe, patienten er udsat for allergener såsom pollen, husstøvmider eller andre dyr.
AVAMYS should only be used for as long as the patient is exposed to the allergen, such as pollen, house dust mites or other animals.
Hvordan virker AVAMYS?
How does AVAMYS work?
Det aktive stof i AVAMYS, fluticasonfuroat, er et kortikosteroid.
The active substance in AVAMYS, fluticasone furoate, is a corticosteroid.
Det fungerer på samme måde som naturligt forekommende kortikosteroide hormoner ved at dæmpe immunsystemets aktivitet, idet det binder til receptorer i forskellige immunceller.
It works in a similar way to naturally-occurring corticosteroid hormones, dampening down the activity of the immune system by attaching to receptors in various types of immune cell.
Dette medfører en reduktion af frigivelsen af stoffer, der er involveret i betændelsesprocessen, f. eks. histamin, hvilket reducerer de allergiske symptomer.
This leads to a reduction the release of substances that are involved in the inflammation process, such as histamine, reducing the symptoms of allergy.
Hvordan blev AVAMYS undersøgt?
How has AVAMYS been studied?
Virkningerne af AVAMYS blev først afprøvet i forsøgsmodeller, inden de blev undersøgt hos mennesker.
The effects of AVAMYS were first tested in experimental models before being studied in humans.
Effekten af AVAMYS blev undersøgt i seks hovedforsøg, der omfattede næsten 2500 patienter, hvor AVAMYS blev sammenlignet med placebo.
The effectiveness of AVAMYS was studied in six main studies involving almost 2,500 patients, which compared AVAMYS with placebo (a dummy treatment).
De første fire undersøgelser beskæftigede sig med AVAMYS anvendt på voksne og unge fra 12 år.
The first four studies looked at AVAMYS used in adults and adolescents aged 12 years or over.
Tre af disse var kortvarige undersøgelser, der 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Three were short-term studies lasting two weeks and involved a total of 886 patients with seasonal allergic rhinitis (hay fever), while the fourth lasted 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Reproduction is authorised provided the source is acknowledged. varede to uger og omfattede i alt 886 patienter med sæsonbestemt allergisk rhinitis (høfeber), mens det fjerde varede fire uger og omfattede 302 patienter med perenniale (ikke- sæsonbestemte) allergier, f. eks. allergier over for dyreskæl (hud og hår).
Reproduction is authorised provided the source is acknowledged. four weeks and involved 302 patients with perennial (non-seasonal) allergies, such as allergies to animal dander (skin and hair).
De sidste to undersøgelser blev udført på børn mellem to og 11 år, hvor to doser AVAMYS blev sammenlignet med placebo.
The last two studies were carried out in children aged between two and 11 years, in which two doses of AVAMYS were compared with placebo.
Den første omfattede 558 børn med perennial allergisk rhinitis, og den andet omfattede 554 børn med sæsonbestemt allergisk rhinitis.
The first involved 558 children with perennial allergic rhinitis and the second involved 554 children with seasonal allergic rhinitis.
Den vigtigste målestok for virkningen i alle undersøgelser var forandringen af fire allergisymptomer med indflydelse på næsen.
In all studies, the main measure of effectiveness was the change in four symptoms of allergy affecting the nose.
Hvilken fordel viser undersøgelserne, at der er ved AVAMYS?
What benefit has AVAMYS shown during the studies?
AVAMYS var mere effektiv end placebo med hensyn til at reducere symptomer ved allergisk rhinitis hos patienter fra seks år.
AVAMYS was more effective than placebo at reducing symptoms of allergic rhinitis in patients aged six years and over.
I undersøgelserne med sæsonbestemt allergisk rhinitis hos voksne og unge reducerede AVAMYS symptomscoren fra et udgangspunkt på omkring 9 point med mellem 3, 6 og 5, 4 point i løbet af to uger sammenlignet med en reduktion på 2, 3 til 3, 7 ved brug af placebo.
In the studies of seasonal allergic rhinitis in adults and adolescents, AVAMYS reduced symptom scores from a starting point of around 9 points by between 3.6 and 5.4 points over two weeks, compared with a reduction of 2.3 to 3.7 points with placebo.
I undersøgelsen med perennial allergisk rhinitis reducerede AVAMYS scoren med 3, 6 point efter fire uger sammenlignet med en reduktion på 2, 8 point med placebo.
In the study of perennial allergic rhinitis, AVAMYS reduced scores by 3.6 points after four weeks, compared with a reduction of 2.8 points with placebo.
Det var dog ikke muligt at afgøre, om AVAMYS virkede hos børn under seks år, fordi der deltog for få børn i den aldersgruppe i undersøgelsen.
However, it was not possible to determine if AVAMYS worked in children below the age of six years, because there were too few children below this age included the studies.
Hvilken risiko er der forbundet med AVAMYS?
What is the risk associated with AVAMYS?
Den hyppigste bivirkning ved AVAMYS (som ses hos flere end 1 patient ud af 10) er næseblod.
The most common side effect with AVAMYS (seen in more than 1 patient in 10) is epistaxis (nosebleeds).
Den vil generelt være mild eller moderat og har en tendens til at påvirke voksne, der bruger AVAMYS i mere end seks uger.
This is generally mild or moderate and tends to affect adults who have used AVAMYS for more than six weeks.
Den fuldstændige liste over de indberettede bivirkninger ved AVAMYS fremgår af indlægssedlen.
For the full list of all side effects reported with AVAMYS, see the Package Leaflet.
AVAMYS må ikke anvendes af personer, der er allergiske over for fluticasonfuroat eller nogle af de øvrige indholdsstoffer.
AVAMYS should not be used in people who are allergic to fluticasone furoate or any of the other ingredients.
Hvorfor blev AVAMYS godkendt?
Why has AVAMYS been approved?
Udvalget for Humanmedicinske Lægemidler (CHMP) fandt, at fordelene ved AVAMYS er større end risiciene ved behandling af symptomer på allergisk rhinitis hos patienter fra seks år.
The Committee for Medicinal Products for Human Use (CHMP) decided that AVAMYS’ s benefits are greater than its risks for the treatment of the symptoms of allergic rhinitis in patients aged six years or over.
Udvalget anbefalede udstedelse af markedsføringstilladelse for AVAMYS.
The Committee recommended that AVAMYS be given marketing authorisation.
Andre oplysninger om AVAMYS:
Other information about AVAMYS:
Europa- Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for AVAMYS til GLAXO Group Ltd den 11. januar 2008.
The European Commission granted a marketing authorisation valid throughout the European Union for AVAMYS to Glaxo Group Ltd on 11 January 2008.
Den fuldstændige EPAR om AVAMYS findes her.
The full EPAR for AVAMYS can be found here.
Indhold (Koncentration)
Content
27, 5 mikg/ pust
27.5 micrograms/ spray
Næsespray, suspension
Nasal spray suspension
Glasflaske i plastkappe
Bottle (glass) in plastic device
AVAMYS 27, 5 mikrogram/ pust næsespray, suspension
AVAMYS 27.5 micrograms/ spray nasal spray suspension
Et pust afgiver 27, 5 mikrogram fluticasonfuroat.
Each spray actuation delivers 27.5 micrograms of fluticasone furoate.
Voksne og unge (fra 12 år) og børn (6- 11 år)
Adults, adolescents (12 years and over) and children (6 – 11 years)
Avamys er indiceret til behandling af: • symptomer på allergisk rhinitis
Avamys is indicated for the treatment of: • the symptoms of allergic rhinitis
Dette lægemiddel er kun til intranasal anvendelse.
Fluticasone furoate nasal spray is for administration by the intranasal route only.
Voksne og unge (fra 12 år) Den anbefalede initialdosis er 2 pust (27, 5 mikrogram fluticasonfuroat/ pust) i hvert næsebor 1 gang daglig (døgndosis i alt 110 mikrogram).
Adults and Adolescents (12 years and over) The recommended starting dose is two spray actuations (27.5 micrograms of fluticasone furoate per spray actuation) in each nostril once daily (total daily dose, 110 micrograms).
Børn (6- 11 år) Den anbefalede initialdosis er 1 pust (27, 5 mikrogram fluticasonfuroat/ pust) i hvert næsebor 1 gang daglig (døgndosis i alt 55 mikrogram).
Children (6 to 11 years of age) The recommended starting dose is one spray actuation (27.5 micrograms of fluticasone furoate per spray actuation) in each nostril once daily (total daily dose, 55 micrograms).
Børn under 6 år:
2 Children under 6 years of age:
5. 1 og 5. 2).
The experience in children under the age of 6 years is limited (see section 5.1 and 5.2).
2 Ældre patienter:
Elderly Patients:
5. 2).
No dose adjustment is required in this population (see section 5.2).
Patienter med nedsat nyrefunktion:
Renal Impaired Patients:
Patienter med nedsat leverfunktion:
Hepatic Impaired Patients:
Der er ikke behov for dosisændringer til patienter med mild til moderat hepatisk insufficiens.
No dose adjustment is required in mild to moderate hepatic impairment.
4. 4 og 5. 2).
There are no data in patients with severe hepatic impairment (see section 4.4 and 5.2).
Næsesprayen skal kun klargøres igen, hvis hætten ikke har været på i 5 dage, eller hvis næsesprayen ikke har været anvendt i over en måned.
Re-priming (approximately 6 sprays until a fine mist is seen) is only necessary if the cap is left off for 5 days or the intranasal device has not been used for 30 days or more.
Overfølsomhed over for det aktive stof eller over for et eller flere af hjælpestofferne.
Hypersensitivity to the active substance or to any of the excipients of Avamys.
4. 2 og 5. 2).
Fluticasone furoate undergoes extensive first-pass metabolism, therefore the systemic exposure of intranasal fluticasone furoate in patients with severe liver disease is likely to be increased.
4. 5).
Ritonavir Concomitant administration with ritonavir is not recommended because of the risk of increased systemic exposure of fluticasone furoate (see section 4.5).
5. 2).
These effects vary between patients and different corticosteroids (see section 5.2).
Hverken hos voksne, unge eller børn førte 110 mikrogram fluticasonfuroat 1 gang daglig til suppression af hypothalamus- hypofyse- binyrebarkfunktionen (HPA).
Fluticasone furoate 110 micrograms once daily was not associated with hypothalamic-pituitary-adrenal (HPA) axis suppression in adult, adolescent or paediatric subjects.
5. 1).
In addition, consideration should be given to referring the patient to a paediatric specialist (see section 5.1).
Avamys indeholder benzalkoniumchlorid.
Avamys contains benzalkonium chloride.
Der sker en betragtelig first pass- metabolisme af fluticasonfuroat ved hjælp af cytokrom- P450 3A4.
3 Fluticasone furoate is rapidly cleared by extensive first pass metabolism mediated by the cytochrome P450 3A4.
3 bør ritonavir ikke gives samtidig på grund af risikoen for øget systemisk påvirkning af fluticasonfuroat.
Based on data with another glucocorticoid (fluticasone propionate), that is metabolised by CYP3A4, co- administration with ritonavir is not recommended because of the risk of increased systemic exposure of fluticasone furoate.
Forsigtighed tilrådes ved samtidig behandling med potente CYP3A4- hæmmere, da øget systemisk påvirkning ikke kan udelukkes.
Caution is recommended when co-administering fluticasone furoate with potent CYP3A4 inhibitors as an increase in systemic exposure cannot be ruled out.
I en interaktionsundersøgelse, hvor fluticasonfuroat blev givet samtidig med den potente CYP3A4- hæmmer ketoconazol, var koncentrationen af fluticasonpropionat målbar hos flere i gruppen, der fik ketoconazol (hos 6 ud af 20), i sammenligning med placebogruppen (hos 1 ud af 20).
In a drug interaction study of intranasal fluticasone furoate with the potent CYP3A4 inhibitor ketoconazole there were more subjects with measurable fluticasone furoate concentrations in the ketoconazole group (6 of the 20 subjects) compared to placebo (1 out of 20 subjects).
4. 4).
This small increase in exposure did not result in a statistically significant difference in 24 hour serum cortisol levels between the two groups (see section 4.4).
Ud fra data om enzyminduktion og - inhibition er der ikke teoretisk grundlag for at forvente metaboliske interaktioner mellem fluticasonfuroat og cytokrom- P450- medieret metabolisme af andre stoffer ved klinisk relevante intranasale doser.
The enzyme induction and inhibition data suggest that there is no theoretical basis for anticipating metabolic interactions between fluticasone furoate and the cytochrome P450 mediated metabolism of other compounds at clinically relevant intranasal doses.
5. 2).
This is not likely to be relevant for humans given recommended nasal doses which results in minimal systemic exposure (see section 5.2).
Hyppigheden defineres således: meget almindelig (≥1/ 10); almindelig (≥1/ 100 til < 1/ 10); ikke almindelig (≥1/ 1. 000 til < 1/ 100); sjælden (≥1/ 10. 000 til < 1/ 1. 000) og meget sjælden (< 1/ 10. 000).
Very common > 1/ 10; Common > 1/ 100 to< 1/10; Uncommon > 1/1000 to< 1/100; Rare > 1/10,000 to < 1/ 1000; Very rare < 1/10,000.
Luftveje, thorax og mediastinum Meget almindelig Almindelig
Respiratory, thoracic and mediastinal disorders Very common Common
Epistaxis Intranasale ulcerationer
Epistaxis Nasal ulceration
Epistaxis var generelt mild til moderat i intensitet.
Epistaxis was generally mild to moderate in intensity.
6 uger).
In adults and adolescents, the incidence of epistaxis was higher in longer-term use (more than 6 weeks) than in short-term use (up to 6 weeks).
4. 9 Overdosering
4 4.9 Overdose
5. 2).
In a bioavailability study, intranasal doses of up to 2640 micrograms per day were administered over three days with no adverse systemic effects observed (see section 5.2).
4 5. 1 Farmakodynamiske egenskaber
5.1 Pharmacodynamic properties
Kortikosteroider, ATC- kode:
ATC code: